• 1. 青島大學(xué)醫(yī)學(xué)院附屬醫(yī)院神經(jīng)內(nèi)科,青島,2660032. 北京大學(xué)第一醫(yī)院,神經(jīng)內(nèi)科,北京,100034;

目的 　通過(guò)循證醫(yī)學(xué)的方法學(xué)探討格林-巴林綜合征(GBS)的治療.
方法 　采用循證醫(yī)學(xué)的方法,根據(jù)具體病例提出問(wèn)題,并進(jìn)行文獻(xiàn)檢索和文獻(xiàn)評(píng)價(jià).
結(jié)果 　根據(jù)GBS的激素、血漿置換和免疫球蛋白治療方面的Cochrane證據(jù)指導(dǎo)GBS的免疫治療,根據(jù)臨床試驗(yàn)的結(jié)果來(lái)指導(dǎo)GBS呼吸衰竭等相關(guān)問(wèn)題的處理.
結(jié)論 　紅循證醫(yī)學(xué)的指導(dǎo)下能夠更好治療GBS患者,并促進(jìn)GBS治療研究方法學(xué)的提高.

引用本文： 李海峰,袁錦楣. 急性格林-巴利綜合征的循證醫(yī)學(xué)治療實(shí)踐初探. 中國(guó)循證醫(yī)學(xué)雜志, 2003, 03(3): 238-241. doi: 復(fù)制

1. ［1］袁錦楣,李海峰格林-巴利綜合征的最新進(jìn)展[J].中國(guó)實(shí)用內(nèi)科雜志2000;20:38-40.
2. ［2］Hughes RA, van Der Meche FG. Corticosteroids for Guillain-Barresyndrome (Cochrane Review)[M/CD]. The Cochrane Library, Issue 1, 2002.
3. ［3］Raphael JC, Chevret S, Hughes RA, et al. Plasma exchange for Guillain-Barre syndrome (Cochrane Review) [M/CD]. The Cochrane Library, Issue 1, 2002.
4. ［4］Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome[J]. Lancet 1997; 349: 225-230.
5. ［5］Wollinsky KH, Hulser PJ, Brinkmeier H, et al. CSF filtration is an effective treatment of Guillain-Barre syndrome: a randomized clinical trial[J]. Neurology 2001; 57: 774-780.
6. ［6］Hughes RA, Raphael .JC, Swan AV, et al. Intravenous immunoglobulin for Guillain-Barre syndrome (Cochrane Review) [M/CD]. The Cochrane Library, Issue 1, 2002.
7. ［7］Sharshar T, ChevretS, Bourdain F, et al. Early predictors of mechanical ventilation in Guillain-Barre syndrome[J]. Crit Care Med 2003;31: 278-283.
8. ［8］Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barre syndrome[J]. Arch Neurol 2001; 58:893-898.
9. ［9］Chevrolet JC, Deleamont P. Repeated vital capacity measurements as predictive parameters for mechanical ventilation need and weaning success in the Guillain-Barre syndrome[J]. Am Rev Respir Dis 1991;144:814-818.
10. ［10］Wijdicks EFM, Borel CO. Respiratory management in acute neurologic illness[J]. Neurology 1998; 50: 11-20.
11. ［11］Hughes RA. Management of acute neuromuscular paralysis[J]. J R Coll Physicians Lond 1998; 322: 254-259.
12. ［12］Newton-John H. Prevention of pulmonary complications in severe Guillain-Barre syndrome by early assisted ventilation[J]. Med J Aust 1985; 142: 444-445.
13. ［13］Fletcher DD, Lawn ND, Wolter TD, et al. Long-term outcome in patients with Guillain-Barre syndrome requiring mechanical ventilation[J]. Neurology 2000; 54:2311-2315.
14. ［14］Hughes RA. Systematic reviews of treatment for inflammatory demyelinating neuropathy[J]. JAnat 2002; 200:331-339.
15. ［15］李海峰,叢志強(qiáng)Guillain-Barre綜合征治療進(jìn)展[J].臨床神經(jīng)病學(xué)雜志2002;15:317-319.
16. ［16］Esperou H, Jars-Guincestre MC, Bolgert F, et al. Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barre syndrome. French Cooperative Group on Plasma Exchange in GuillainBarre Syndrome[J]. Intensive Care Med 2000; 26: 1094-1100.
  1. 1. ［1］袁錦楣,李海峰格林-巴利綜合征的最新進(jìn)展[J].中國(guó)實(shí)用內(nèi)科雜志2000;20:38-40.
  2. 2. ［2］Hughes RA, van Der Meche FG. Corticosteroids for Guillain-Barresyndrome (Cochrane Review)[M/CD]. The Cochrane Library, Issue 1, 2002.
  3. 3. ［3］Raphael JC, Chevret S, Hughes RA, et al. Plasma exchange for Guillain-Barre syndrome (Cochrane Review) [M/CD]. The Cochrane Library, Issue 1, 2002.
  4. 4. ［4］Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome[J]. Lancet 1997; 349: 225-230.
  5. 5. ［5］Wollinsky KH, Hulser PJ, Brinkmeier H, et al. CSF filtration is an effective treatment of Guillain-Barre syndrome: a randomized clinical trial[J]. Neurology 2001; 57: 774-780.
  6. 6. ［6］Hughes RA, Raphael .JC, Swan AV, et al. Intravenous immunoglobulin for Guillain-Barre syndrome (Cochrane Review) [M/CD]. The Cochrane Library, Issue 1, 2002.
  7. 7. ［7］Sharshar T, ChevretS, Bourdain F, et al. Early predictors of mechanical ventilation in Guillain-Barre syndrome[J]. Crit Care Med 2003;31: 278-283.
  8. 8. ［8］Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barre syndrome[J]. Arch Neurol 2001; 58:893-898.
  9. 9. ［9］Chevrolet JC, Deleamont P. Repeated vital capacity measurements as predictive parameters for mechanical ventilation need and weaning success in the Guillain-Barre syndrome[J]. Am Rev Respir Dis 1991;144:814-818.
  10. 10. ［10］Wijdicks EFM, Borel CO. Respiratory management in acute neurologic illness[J]. Neurology 1998; 50: 11-20.
  11. 11. ［11］Hughes RA. Management of acute neuromuscular paralysis[J]. J R Coll Physicians Lond 1998; 322: 254-259.
  12. 12. ［12］Newton-John H. Prevention of pulmonary complications in severe Guillain-Barre syndrome by early assisted ventilation[J]. Med J Aust 1985; 142: 444-445.
  13. 13. ［13］Fletcher DD, Lawn ND, Wolter TD, et al. Long-term outcome in patients with Guillain-Barre syndrome requiring mechanical ventilation[J]. Neurology 2000; 54:2311-2315.
  14. 14. ［14］Hughes RA. Systematic reviews of treatment for inflammatory demyelinating neuropathy[J]. JAnat 2002; 200:331-339.
  15. 15. ［15］李海峰,叢志強(qiáng)Guillain-Barre綜合征治療進(jìn)展[J].臨床神經(jīng)病學(xué)雜志2002;15:317-319.
  16. 16. ［16］Esperou H, Jars-Guincestre MC, Bolgert F, et al. Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barre syndrome. French Cooperative Group on Plasma Exchange in GuillainBarre Syndrome[J]. Intensive Care Med 2000; 26: 1094-1100.